SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Attention centers on the approaching FDA decision on Capricors deramiocel for Duchenne muscular dystrophy, with traders weighing the companys amended application and longer-term upper-limb data alongside recent FDA discussion of flexibility in rare-disease reviews. Many are bullish and read commercial hiring as a sign of launch preparation, while skeptics stress that approval is uncertain given the earlier negative review and debate over the evidence; some also cite Inovios separate FDA approval as a positive sentiment signal.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTX is climbing toward a 52-week high as traders position for anticipated Q3 results, with BRIUMVIs sales growth adding to optimism. Buyout and short-squeeze theories are circulating, but the acquisition talk is unconfirmed, and some traders question whether earnings expectations are already reflected in the run-up.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Inovios FDA approval of a competing treatment for recurrent respiratory papillomatosis has raised concerns about new competition for Precigens PAPZIMEOS. Traders debate the threat: some see a serious challenge, while others argue Precigen retains an advantage from its commercial head start and full approval, and view the selloff as an overreaction.

Okta, Inc. engages in the provision of an identity management platform for enterprises. The firm operates through the following geographical segments: United States and International. Its products include single sign-on, multi-factor authentication, access gateway, API access management, authentication, adaptive MFA and lifecycle management. The company was founded by Todd McKinnon and J. Frederic Kerrest in 2009 and is headquartered in San Francisco, CA.

Okta Inc - Ordinary Shares - Class A

Okta Inc

Traders are discussing Oktas reported addition to the S&P 500 in place of KVUE, with some anticipating index-related buying and others warning of a sell-the-news reaction. Separately, claims of a DHS data exposure involving Oktas login system are adding bearish concern, though those claims are not established in the discussion.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that Medicare reimbursement for DefenCath could decline after early 2027 has fueled concerns about pricing and CorMedixs largest revenue driver. Traders are divided: some see the comments as a serious commercial risk, while others argue DaVitas outlook is preliminary and point to CMSs reimbursement estimate as a counterweight.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.

Mineralys Therapeutics Inc

MLYS is under pressure amid concerns that the slow early commercial ramp for AstraZenecas competing hypertension drug could signal a challenging launch and weaker near-term sales prospects for lorundrostat. Traders disagree on whether that undermines Mineralyss commercial outlook, with some emphasizing the upcoming FDA decision and clinical data while others question its ability to compete independently.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

BNB (BNB) is a cryptocurrency . BNB has a current supply of 131,511,396.41. The last known price of BNB is 698.79071116 USD and is down -6.08 over the last 24 hours. It is currently trading on 3523 active market(s) with $4,017,835,584.29 traded over the last 24 hours. More information can be found at https://bnbchain.org/en.

Binance

A reported major Binance security breach, with withdrawals temporarily suspended and billions in crypto reportedly affected, is driving attention to BNB and broader crypto-market concerns. Traders are debating whether the incident threatens trust in Binance and warrants further selling, while others view the selloff as an overreaction; claims of an inside job remain speculation.

Permian Resources Corp. is an oil and natural gas company, which focuses on returns to stakeholders through the responsible acquisition, optimization and development of crude oil and associated liquids-rich natural gas reserves. The company was founded on December 18, 2025 and is headquartered in Midland, TX.

Permian Resources Holdings Inc. - Ordinary Shares - Class A

Permian Resources Corp - Ordinary Shares - Class A

Permian Resources is being discussed amid volatile crude prices and shifting Middle East supply risks, especially tensions and shipping disruptions around the Strait of Hormuz. Traders debate why PR often fails to track oils moves, while some point to the companys production growth, guidance and dividends as support for a longer-term bullish view.

Centrus Energy Corp. engages in the supply of nuclear fuel and services for the nuclear power industry. It operates through the Low-Enriched Uranium (LEU) and Technical Solutions segments. The LEU segment includes various components of nuclear fuel to utilities from its global network of suppliers. The Technical Solutions segment offers advanced engineering, design, and manufacturing services to government and private sector customers, and is deploying advanced nuclear fuel production capabilities to power existing, and next-generation reactors around the world. The company was founded in October 1992 and is headquartered in Bethesda, MD.

Centrus Energy Corp - Ordinary Shares - Class A

Centrus Energy Corp 

Centruss steep selloff is the dominant topic, with traders citing share dilution and the cost and execution risks of expanding enrichment capacity, alongside weakness across nuclear stocks. Bulls point to its strategic U.S. HALEU supply role and government contracts as long-term support, while others question the valuation and whether the decline has further to run.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BA Stock Heads For Weekly Loss: CEO Maps Path To $10B Cash Flow, 737 Stabilization Slips Into 2027  

Equity

Boeing expects to reach the 737 production target of 47 aircraft per month in 2027, later than planned. 


Should You Invest in the iShares U.S. Industrials ETF (IYJ)?

GE Stock Rises Premarket: GE Aerospace CEO Assures Demand Remains 'Solid,' Retail Agrees    

CEO Larry Culp cited solid demand as third-quarter revenue rose 18% and profit jumped 30%. 


GE Stock Inches Up Overnight On $2.8B Navy Contract As Hypersonic Program Advances 

GE Aerospace will maintain F414 engines through 2031 while developing a new HyCAT hypersonic test vehicle. 

CAT Stock Heads For Second Weekly Loss: Is Caterpillar's AI Rally Fading? 

Caterpillar is losing momentum as investors weigh rich valuations, tariffs and execution risks.

GE Stock Charts Golden Cross As Strong Aviation Demand, Defense Growth Fuel Momentum 

A major factor behind GE Aerospace’s growth has been the ongoing strain within the global aircraft production system and defense demand.


South Korea's $350B U.S. Investment Pledge: ETFs That Could Gain

South Korea's $350B U.S. investment pledge could lift the country's export momentum while boosting key U.S. sectors. Here are some ETFs that may benefit.

iShares Trust - iShares U.S. Industrials ETF

Bullish Sentiment

<ul class="summary-bullets"><li>Boeing CEO Robert Ortberg said the 737 production could need additional time to reach stabilization,&nbsp;</li><li>The FAA approved the delayed 737 Max 10 last week, which has over 1,550 orders.&nbsp;</li><li>Boeing expects free cash flow to increase from $2 billion in 2026 to $10 billion by 2029.</li></ul>Boeing Co. (BA) stock is heading for a weekly loss as CEO Robert Ortberg outlined a path to $10 billion in free cash flow by 2029, with the company’s 737 production stabilization taking longer than expected. Boeing expects to reach its target production rate of 47 jets monthly in 2027, with cash flow improving over the next three years.&nbsp;<a href="https://stocktwits.com/symbol/BA">Boeing stock</a> edged up 0.2% overnight Tuesday after a 10% drop in regular trading.&nbsp;<h2 class="st-heading-2">Boeing’s 737 Production Ramp Faces Delays</h2>During the third-quarter (Q3) earnings call, Ortberg said Boeing is working to establish a manufacturing pace of 47 737 aircraft per month and needs additional time to sustain its targeted production rate.“On 737, we continue to work towards stabilizing production at 47 airplanes per month. Our factory key performance indicators are performing well, particularly in the final assembly, where we've seen a 40% improvement in rework since the start of last year. However, as I mentioned at a conference last month, it is taking us longer than we had expected to demonstrate performance at rate 47. We're making progress, but we still have more work to do, and I'm expecting it will take us into next year to get fully stable at this rate.”&nbsp;Boeing received U.S. approval last week for the 737 Max 10, its largest model in the 737 Max family, after a six-year wait. The plane has over 1,550 orders, making up more than 30% of Boeing’s total 737 Max orders. The delay followed safety checks after two deadly 737 Max 8 crashes in 2018 and 2019.&nbsp;<h2 class="st-heading-2">Boeing Sets Out Cash Flow Road Map</h2>Ortberg acknowledged that shareholders have struggled to predict how Boeing’s operational improvements would translate into the balance sheet. The company expects to generate roughly $2 billion in free cash flow in 2026, followed by approximately $3 billion in 2027. That 2027 outlook includes additional capital spending to develop the F/A-XX program, the U.S. Navy’s sixth-generation fighter jet contract.Boeing expects free cash flow to rise to about $6 billion in 2028 before reaching its $10 billion goal in 2029. Ortberg expects the financial recovery to pick up as some existing pressures ease.The 777X program will remain a drag in the near term. “With respect to program cash flow, we continue to expect 2027 to be a significant use of cash with 2028 improving before turning positive in 2029,” said CFO Jesus Malave of the 777X.&nbsp;Jefferies&nbsp;called Boeing’s free cash flow targets “disappointing,” noting that each year’s goal had slipped by about a year. In Q3, Boeing&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/boeing-q3-loss-narrows-sharply-ceo-says-we-have-more-work-to-do/cZUeX0gRBCk">reported&nbsp;</a>a loss of $0.34 per share, an improvement from a loss of $7.47 per share a year earlier but worse than analysts’ estimate of a loss of $0.25 per share, according to Fiscal.ai.&nbsp;<h2 class="st-heading-2">BA Stock: Retail View&nbsp;</h2>However, on Stocktwits, retail sentiment for BA improved to ‘extremely bullish’ from ‘bullish’. The stock recorded a 900% surge in message volume over the past 24 hours.&nbsp;A user&nbsp;<a href="https://stocktwits.com/Guvnor/message/667496470">said</a>, “Just turbulence. We'll be back to smooth flying soon.”BA stock has cratered 22% year-to-date.&nbsp;Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/jblu-stock-soars-to-best-day-in-18-months-after-ceo-geraghty-calms-credit-concerns-highlights-business-progress/cZUems9RBCU">JBLU Stock Soars To Best Day In 18 Months After CEO Geraghty Calms Credit Concerns, Highlights Business Progress</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Boeing 737 MAX 10 prepares to take off for its first flight at Renton Municipal Airport.

Boeing Co. (BA) stock is heading for a weekly loss as CEO Robert Ortberg outlined a path to $10 billion in free cash flow by 2029, with the company’s 737 production stabilization taking longer than expected. Boeing expects to reach its target production r

BA Stock Heads For Weekly Loss: CEO Maps Path To $10B Cash Flow, 737 Stabilization Slips Into 2027

Boeing Co

iShares Dow Jones US Aerospace & Defense

iShares U.S. Industrials ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Fundamentals

Info

IYJ News